Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;27(12):3886-3904.
doi: 10.1007/s10461-023-04104-1. Epub 2023 Jul 26.

Feasibility, Acceptability and Appropriateness of MedViewer: A Novel Hair-Based Antiretroviral Real-Time Clinical Monitoring Tool Providing Adherence Feedback to Patients and Their Providers

Carol E Golin  1   2   3   4 , Elias P Rosen  5 , Ella Gillespie Ferguson  6 , Nzi Rose Perry  6 , Amanda Jacqueline Poliseno  5 , Alexandra J Munson  6   7 , Alexandra Davis  6 , Lauren M Hill  8 , Jessica Keys  6 , Nicole R White  6   5 , Claire E Farel  6   7 , Angela Kashuba  6   5
Affiliations

Feasibility, Acceptability and Appropriateness of MedViewer: A Novel Hair-Based Antiretroviral Real-Time Clinical Monitoring Tool Providing Adherence Feedback to Patients and Their Providers

Carol E Golin et al. AIDS Behav. 2023 Dec.

Abstract

Antiretroviral therapy (ART) adherence is key to achieving viral load suppression and ending the HIV epidemic but monitoring and supporting adherence using current interventions is challenging. We assessed the feasibility, acceptability and appropriateness of MedViewer (MV), a novel intervention that provides real-time adherence feedback for patients and providers using infra-red matrix-assisted laser desorption electrospray ionization (IR-MALDESI) for mass spectrometry imaging of daily ART concentrations in patients' hair. We used mixed methods to feasibility test MV at a busy Infectious Diseases (ID) clinic, enrolling 16 providers and 36 patients. Providers underwent standardized training; patients and providers watched an 8-min informational video about MV. We collected patient and provider data at baseline and within 24 h of clinic visits and, with patients, approximately 1 month after clinic visits. MedViewer was feasible, liked by patients and providers, and perceived to help facilitate adherence conversations and motivate patients to improve adherence. Trial Registration: NCT04232540.

Keywords: Antiretroviral adherence; Clinical drug monitoring; Interventions; Medication adherence.

PubMed Disclaimer

Conflict of interest statement

Competing interests The authors have no competing interests or conflicts of interest.

Figures

Fig. 1
Fig. 1
Example MedViewer report patient (calendar) version and provider (bar chart) version
See this image and copyright information in PMC

References

    1. Global Statistics | HIV.gov [Internet]. [cited 2022 Mar 31]. https://www.hiv.gov/hivbasics/overview/dataandtrends/globalstatistics.
    1. The Lancet HIV. U=U taking off in 2017. Lancet HIV. 2017;4:e475. - PubMed
    1. –90–90: good progress, but the world is off-track for hitting the 2020 targets [Internet]. UNAIDS. 2020. [cited 2022 Apr 4]. https://www.unaids.org/en/909090.
    1. Bangsberg DR, Haberer JE. Lifetime HIV antiretroviral therapy adherence intervention: timing is everything: comment on “Managed problem solving for antiretroviral therapy adherence.” JAMA Intern Med. 2013;173:306–7. - PMC - PubMed
    1. Carvalho PP, Barroso SM, Coelho HC, Penaforte FRO. Factors associated with antiretroviral therapy adherence in adults: an integrative review of literature. Cien Saude Colet. 2019;24:2543–55. - PubMed

Associated data